Page last updated: 2024-12-07

lc 6

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LC 6: RN given refers to (trans)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID106696
CHEMBL ID3249770
MeSH IDM0067191

Synonyms (9)

Synonym
lc 6
(3bs,8br)-3,3b,4,5,8,8b,9,10-octahydroindazolo[7,6-g]indazole
66818-22-2
trans-2,3b,4,5,7,8b,9,10-octahydronaphtho(1,2-c:5,6-c')dipyrazole
lc-6
naphtho(1,2-c:5,6-c')dipyrazole, 2,3b,4,5,7,8b,9,10-octahydro-, trans-
CHEMBL3249770
(3br,8bs)-2,3b,4,5,7,8b,9,10-octahydroindazolo[7,6-g]indazole
AKOS040747024
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1134815Antiallergic activity in Sprague-Dawley rat assessed as inhibition of mouse antiserum-induced passive cutaneous anaphylaxis at 25 mg/kg, po administered 1 hr before antiserum challenge measured after 30 mins by Evans blue staining relative to control1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
trans-2,3b,4,5,7,8b,9,10-Octahydronaphtho[1,2-c:5,6-c']dipyrazole, a new orally active antiallergic compound.
AID1134819Antiallergic activity in Sprague-Dawley rat assessed as inhibition of mouse antiserum-induced passive cutaneous anaphylaxis at 0.5 mg/kg, iv administered with antiserum measured after 30 mins by Evans blue staining relative to control1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
trans-2,3b,4,5,7,8b,9,10-Octahydronaphtho[1,2-c:5,6-c']dipyrazole, a new orally active antiallergic compound.
AID1134817Antiallergic activity in Sprague-Dawley rat assessed as inhibition of mouse antiserum-induced passive cutaneous anaphylaxis at 100 mg/kg, po administered 1 hr before antiserum challenge measured after 3 hrs by Evans blue staining relative to control1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
trans-2,3b,4,5,7,8b,9,10-Octahydronaphtho[1,2-c:5,6-c']dipyrazole, a new orally active antiallergic compound.
AID1134816Antiallergic activity in Sprague-Dawley rat assessed as inhibition of mouse antiserum-induced passive cutaneous anaphylaxis at 50 mg/kg, po administered 1 hr before antiserum challenge measured after 30 mins by Evans blue staining relative to control1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
trans-2,3b,4,5,7,8b,9,10-Octahydronaphtho[1,2-c:5,6-c']dipyrazole, a new orally active antiallergic compound.
AID1134820Antiallergic activity in po dosed Sprague-Dawley rat assessed as inhibition of mouse antiserum-induced passive cutaneous anaphylaxis administered 1 hr before antiserum challenge measured after 30 mins by Evans blue staining1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
trans-2,3b,4,5,7,8b,9,10-Octahydronaphtho[1,2-c:5,6-c']dipyrazole, a new orally active antiallergic compound.
AID1134821Antiallergic activity in Sprague-Dawley rat assessed as inhibition of mouse antiserum-induced passive cutaneous anaphylaxis at 5 to 6 times ED50 mg/kg, po administered 1 hr before antiserum challenge measured after 30 mins by Evans blue staining relative 1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
trans-2,3b,4,5,7,8b,9,10-Octahydronaphtho[1,2-c:5,6-c']dipyrazole, a new orally active antiallergic compound.
AID1134818Antiallergic activity in Sprague-Dawley rat assessed as inhibition of mouse antiserum-induced passive cutaneous anaphylaxis at 200 mg/kg, po administered 1 hr before antiserum challenge measured after 6 hrs by Evans blue staining relative to control1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
trans-2,3b,4,5,7,8b,9,10-Octahydronaphtho[1,2-c:5,6-c']dipyrazole, a new orally active antiallergic compound.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.54 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index67.11 (26.88)
Search Engine Supply Index3.25 (0.95)

This Compound (34.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]